|
gptkbp:instanceOf
|
gptkb:chemical_compound
MEK inhibitor
|
|
gptkbp:ATCCode
|
none
|
|
gptkbp:CASNumber
|
391210-10-9
|
|
gptkbp:clinicalTrialPhase
|
Phase II (as of 2023)
|
|
gptkbp:developedBy
|
gptkb:Pfizer
|
|
gptkbp:has_bioavailability
|
not publicly available
|
|
gptkbp:hasInChIKey
|
QXJYYZQXAFYFJA-RYUDHWBXSA-N
|
|
gptkbp:hasMolecularFormula
|
C16H14F3IN2O4
|
|
gptkbp:hasSMILES
|
C1=CC(=C(C=C1N(C2=CC(=C(C=C2F)F)F)C(=O)NCC(CO)O)I)F
|
|
gptkbp:hasUNII
|
6Z5B6HVF6O
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
PD 0325901
|
|
gptkbp:is_investigational_drug
|
true
|
|
gptkbp:IUPACName
|
(R)-N-(2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)benzamide
|
|
gptkbp:legalStatus
|
investigational
|
|
gptkbp:mechanismOfAction
|
inhibits MAPK/ERK pathway
|
|
gptkbp:meltingPoint
|
not publicly available
|
|
gptkbp:molecularWeight
|
482.195 g/mol
|
|
gptkbp:PubChem_CID
|
9915743
CHEMBL354494
8090065
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:synonym
|
gptkb:PD0325901
gptkb:PD-325901
CI-1040 analog
|
|
gptkbp:target
|
gptkb:MEK1
gptkb:MEK2
|
|
gptkbp:used_in
|
cancer research
|
|
gptkbp:bfsParent
|
gptkb:PD0325901
|
|
gptkbp:bfsLayer
|
7
|